Status message

Active context: kki_bg_colors_yellow

A Phase 3, multicenter, three-week, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of flexible doses of oral Ziprasidone in children and adolescents with Bipolar I disorder (current or most recent episode manic)

Principal Investigator:
Robert
Findling

This will be a Phase 3, multicenter, 3-week, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and tolerability of flexibly dosed ziprasidone compared with placebo for the treatment of Bipolar I Disorder. 

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.